Letter in Response to "HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety"

Affiliations

¹ Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
² Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan.
³ Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan.
⁴ Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Free article

Comment

Hiroyasu Yamamoto et al. Am J Nephrol. 2021.

Free article

. 2021;52(12):977-978.

doi: 10.1159/000520156. Epub 2021 Nov 2.

¹ Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
² Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan.
³ Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan.
⁴ Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

No abstract available

Comment on

HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety.
Roger SD, Coyne DW. Roger SD, et al. Am J Nephrol. 2021;52(10-11):894-898. doi: 10.1159/000518073. Epub 2021 Sep 16. Am J Nephrol. 2021. PMID: 34535582 No abstract available.
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Yamamoto H, et al. Am J Nephrol. 2021;52(10-11):884-893. doi: 10.1159/000518072. Epub 2021 Sep 16. Am J Nephrol. 2021. PMID: 34569482 Clinical Trial.
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Yamamoto H, et al. Am J Nephrol. 2021;52(10-11):871-883. doi: 10.1159/000518071. Epub 2021 Sep 16. Am J Nephrol. 2021. PMID: 34569489 Clinical Trial.